Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease

Journal of the American Geriatrics Society

Volumn 52, Issue 7, 2004, Pages 1070-1076

  Galasko, Douglas ^a,b,h   Kershaw, Paul R ^c   Schneider, Lon ^d   Zhu, Young ^e   Tariot, Pierre N ^f,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c Medical Affairs Division   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g Monroe Community Hospital   (United States)

^h Neurology Service   (United States)

Author keywords

Activities of daily living; Alzheimer's disease; Galantamine

Indexed keywords

GALANTAMINE; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DETERIORATION; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; MALE; NOOTROPIC AGENTS; TREATMENT OUTCOME; UNITED STATES;

EID: 3042814742     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2004.52303.x     Document Type: Article

References (33)

1. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11 (Suppl 1):11-18.
2. Newens AJ, Forster DP, Kay DW. Dependency and community care in presenile Alzheimer's disease. Br J Psychiatry 1995;166:777-782.
3. Aguero-Torres H, Fratiglioni L, Guo Z et al. Prognostic factors in very old demented adults: A seven-year follow-up from a population-based survey in Stockholm. J Am Geriatr Soc 1998;46:444-452.
4. Boersma F, Van Den BW, Deeg DJ et al. Survival in a population-based cohort of dementia patients: Predictors and causes of mortality. Int J Geriatr Psychiatry 1999;14:748-753.
5. Knopman DS, Berg JD, Thomas R et al. Nursing home placement is related to dementia progression: Experience from a clinical trial. Neurology 1999;52:714-718.
6. Hope T, Keene J, Gedling K et al. Predictors of institutionalization for people with dementia living at home with a carer. Int J Geriatr Psychiatry 1998;13:682-690.
7. Smith GE, Kokmen E, O'Brien PC. Risk factors for nursing home placement in a population-based dementia cohort. J Am Geriatr Soc 2000;48:519-525.
8. Severson MA, Smith GE, Tangalos EG et al. Patterns and predictors of institutionalization in community-based dementia patients. J Am Geriatr Soc 1994;42:181-185.
9. Tariot PN, Solomon PR, Morris JC et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276.
10. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
11. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
13. Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy under a Slow-Titration Regimen. Titusville, NJ: Janssen Research Foundation, 1999.
14. Galasko D, Bennett D, Sano M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl 2):S33-S39.
15. Caro J, Ward A, Ishak K et al. To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers? BMC Neurol 2002;2:6.
16. Schneider LS, Olin JT, Doody RS et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S22-S32.
17. Cummings JL, Mega M, Gray K et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
18. Smith GE, O'Brien PC, Ivnik RJ et al. Prospective analysis of risk factors for nursing home placement of dementia patients. Neurology 2001;57:1467-1473.
19. Raskind MA, Cyrus PA, Ruzicka BB et al. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. J Clin Psychiatry 1999;60:318-325.
20. Gelinas I, Gauthier S, Cyrus PA. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living. J Geriatr Psychiatry Neurol 2000;13:9-16.
21. Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318:633-638.
22. Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488.
23. Feldman H, Gauthier S, Hecker J et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620.
24. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495.
25. Thal LJ, Ferguson JM, Mintzer J et al. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology 1999;52:1146-1152.
26. Imbimbo BP, Martelli P, Troetel WM et al. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology 1999; 52:700-708.
27. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ 2000;321:1445-1449.
28. Raskind MA, Peskind ER, Wessel T et al. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268.
29. Reed BR, Jagust WJ, Seab JP. Mental status as a predictor of daily function in progressive dementia. Gerontologist 1989;29:804-807.
30. Pfeffer RI, Kurosaki TT, Harrah CH Jr et al. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-329.
31. Ford GR, Haley WE, Thrower SL et al. Utility of Mini-Mental State Exam scores in predicting functional impairment among white and African American dementia patients. J Gerontol A Biol Sci Med Sci 1996; 51A:M185-M188.
32. Perry RJ, Hodges JR. Relationship between functional and neuropsychological performance in early Alzheimer disease. Alzheimer Dis Assoc Disord 2000; 14:1-10.
33. Feldman H, Sauter A, Donald A et al. The Disability Assessment for Dementia Scale: A 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:89-95.